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Abstract: Triclabendazole (TCBZ) resistance is an emerging problem in fascioliasis that is not well understood. Studies including small numbers of parasites fail to capture the complexity of susceptibility
variations between and within Fasciola hepatica populations. As the first step to studying the complex
resistant phenotype–genotype associations, we characterized a large sample of adult F. hepatica with
diverging TCBZ susceptibility. We collected parasites from naturally infected livestock slaughtered in
the Cusco and Cajamarca regions of Peru. These parasites were exposed to TCBZ sulfoxide (TCBZ.SO)
in vitro to determine their susceptibility. We used a motility score to determine the parasite’s viability.
We titrated drug concentrations and times to detect 20% non-viable (susceptible conditions) or 80%
non-viable (resistant conditions) parasites. We exposed 3348 fully motile parasites to susceptible
(n = 1565) or resistant (n = 1783) conditions. Three hundred and forty-one (21.8%) were classified as
susceptible and 462 (25.9%) were classified as resistant. More resistant parasites were found in Cusco
than in Cajamarca (p < 0.001). Resistant parasites varied by slaughterhouse (p < 0.001), month of the
year (p = 0.008), fluke length (p = 0.016), and year of collection (p < 0.001). The in vitro susceptibility
to TCBZ.SO in wildtype F. hepatica was associated with geography, season, and morphometry.
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1. Introduction

iations.

Fascioliasis is a zoonotic trematode infection with wide distribution among humans
and livestock. The infection has been reported in 81 developed and developing countries
around the world and is believed to affect between 2.4 and 17 million people [1–3]. Humans
are commonly infected in rural areas of South America, Africa, and Asia [4]. Livestock
infections cause decreased fertility and production of meat, milk, and wool associated with
significant revenue losses, poverty, and food insecurity [5]. Peru has one of the highest
burdens of fascioliasis with a prevalence of up to 70% in livestock and up to 47% among
children in some communities of the Andes Mountains [6–9].
TCBZ is the only drug active against juvenile and adult stages of the fluke and is
widely used for treatment and control [10,11]. The mechanisms of action are not fully
understood, but as with other benzimidazoles, TCBZ specifically binds to beta-tubulin in
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F. hepatica disrupting the microtubules [12]. TCBZ is rapidly metabolized into TCBZ.SO
and TCBZ sulfone after absorption in the intestine, with the former being more active
and abundant than the latter [12]. Reports of treatment failure and TCBZ resistance
have emerged from endemic areas around the world [13–15]. Resistance to TCBZ has
been reported in the highlands of Peru and documented among humans and livestock.
Ortiz et al. in the Northern Peruvian highlands demonstrated a TCBZ efficacy of 25% on a
F. hepatica isolate obtained from cattle in Cajamarca [16]. Morales et al. reported an efficacy
of 70% after two treatment rounds with TCBZ among children with chronic fascioliasis in
the Cusco highlands, and 12% of the children failed to show parasitological cure despite
repeated treatment courses and high TCBZ doses [13]. The mechanisms of resistance
have not been elucidated, but some studies suggested different mechanisms including
alterations in drug uptake/efflux, increased metabolism of TCBZ.SO to the less-active
sulfone metabolite, and increased glutathione S-transferase detoxification activity [17–20].
A study by Borgsteede et al. suggested that once resistance to TCBZ emerged in farms,
the phenotype persists even after years of stopping its use [21]. Then, the prevention and
active surveillance of the spread of TCBZ resistance in endemic areas is paramount to the
preservation of effective treatment options and control programs for fascioliasis.
TCBZ-susceptible and -resistant F. hepatica strains collected from livestock have been
characterized and maintained in the laboratory for decades [22]. These laboratory adapted
F. hepatica isolates are used as models for in vitro studies of drug susceptibility [23–27].
Even among the limited number of laboratory parasite clones, significant differences in
susceptibility profiles to anthelminthic drugs including TCBZ have been documented.
These differences depend on the parasite’s age, drug and drug dose, and geographic
location [22]. In addition, differences in parasite fitness assessed by infectious capacity,
latent infection periods, and the number of eggs or metacercariae produced have been
reported between laboratory isolates with similar resistance patterns [23,28]. These findings
suggest that TCBZ resistance is a complex problem that not only leads to treatment failures
but may also have broad effects on the parasite’s epidemiology. Thus, understanding how
TCBZ resistance arises and spreads in the natural populations of F. hepatica is critical for the
sustainable control of fascioliasis.
In this study, we report the characterization of a large number of F. hepatica parasites collected from naturally infected livestock with diverging TCBZ susceptibility in different endemic areas of Peru. Considering that TCBZ resistance is likely a polygenic/multifactorial
trait with substantial variation both within and between populations, studies focusing on
a limited number of laboratory or field parasites do not yield the full picture. Baska
˛
et al.
demonstrated differences in the expression of immunomodulatory molecules between
laboratory isolates of F. hepatica and wildtype parasites collected from the field, highlighting
the intraspecies variability that may contribute to discrepancies between studies of small
sample size [29]. A single nucleotide polymorphism in the P-glycoprotein gene was associated with TCBZ resistance in Ireland, but further studies in Latin America and Australia
failed to find the same association [30–32]. Our work based on a broad sampling of field
isolates identifies parasites at opposite extremes of the TCBZ susceptibility spectrum and is
an important first step to a comprehensive evaluation of genotype–phenotype associations
in this globally distributed trematode parasite of public health and economic significance.
2. Results
We collected 9613 F. hepatica parasites from 430 condemned bovid livers. Parasites from
37 condemned livers were discarded due to decreased viability after 48 h of incubation or
bacterial contamination. We selected 3348 F. hepatica for exposure to TCBZ.SO, where 98%
of these were collected from cattle and 2% were collected from sheep. Most parasites were
collected in the Cusco region (61.9%) during 2021 (81.4%) (Table 1). The slaughterhouses
where more flukes were collected were Cajamarca (34.9%) in Cajamarca city and Kayra
(29.4%) in Cusco city. The mean fluke length was 17.7 mm (± 2.86). Almost equal numbers
of flukes were exposed to susceptible conditions (46.7%) or resistant conditions (53.3%).
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The proportion of flukes exposed to susceptible conditions was lower in 2020 compared
to 2021 (32.6% versus 49.9%, p < 0.001) and flukes exposed to susceptible conditions were
shorter than flukes exposed to resistant conditions (17.3 mm ± 2.66 versus 18 mm ± 3,
p < 0.001) (Table 1).
Table 1. Characteristics of the F. hepatica specimens according to TCBZ.SO exposure conditions.

Site
Slaughterhouse

Month *

Year *

Cusco
Cajamarca
Kayra
Anta
San Jeronimo
Cajamarca
San Marcos
Bambamarca
Cajabamba
January
February
March
April
May
June
July
August
September
October
November
December
2020
2021

Total (%)

Exposed 12 h (%)

Exposed 24 h (%)

N = 3348

N = 1565

N = 1783

2074 (61.9)
1274 (38.1)
983 (29.4)
528 (15.8)
563 (16.8)
1170 (34.9)
16 (0.5)
72 (2.2)
16 (0.5)
228 (6.8)
415 (12.4)
152 (4.5)
296 (8.8)
200 (6)
216 (6.5)
294 (8.8)
191 (5.7)
384 (11.5)
312 (9.3)
368 (11)
292 (8.7)
624 (18.6)
2724 (81.4)

966 (61.7)
599 (38.3)
455 (29.1)
252 (16.1)
259 (16.5)
547 (35)
8 (0.5)
36 (2.3)
8 (0.5)
96 (6.1)
167 (10.7)
68 (4.3)
148 (9.5)
100 (6.4)
92 (5.9)
143 (9.1)
95 (6.1)
192 (12.3)
156 (10)
164 (10.5)
144 (9.2)
204 (13)
1361 (87)

1108 (62.1)
675 (37.9)
528 (29.6)
276 (15.5)
304 (17)
623 (34.9)
8 (0.4)
36 (2)
8 (0.4)
132 (7.4)
248 (13.9)
84 (4.7)
148 (8.3)
100 (5.6)
124 (7)
151 (8.5)
96 (5.4)
192 (10.8)
156 (8.7)
204 (11.4)
148 (8.3)
420 (22.9)
1363 (76.4)

* p < 0.05.

Overall, 341 flukes were classified as susceptible, representing 10.2% of all the parasites
tested and 21.8% of the parasites exposed to susceptible conditions. The proportion of
flukes classified as susceptible varied by slaughterhouse (p = 0.024), month of the year
(p = 0.003), and fluke length (p < 0.001) (Table 2). Similarly, 462 flukes were classified as
resistant, representing 13.8% of all the parasites tested and 25.9% of the parasites exposed
to the resistant conditions. A higher proportion of flukes were classified as resistant in
the Cusco region compared to the Cajamarca region (33.8% versus 12.9%, p < 0.001). The
proportion of flukes classified as resistant also varied by slaughterhouse (p < 0.001), month
of the year (p = 0.008), fluke length (p = 0.016), and year of collection (p < 0.001) (Table 2).
The mean length of resistant flukes was significantly higher than the length of susceptible
flukes (18.82 mm (±6.58) versus 16.66 mm (±2.73), p < 0.001).
When the parasites collected in 2020 and 2021 were evaluated together, the pattern of
variation in the distribution of parasites classified as susceptible or resistant was different
depending on the region. In Cusco, the distribution of susceptible F. hepatica fluctuated
without a clear pattern (p = 0.006) while there was a marked increase in the proportion
of resistant F. hepatica observed between the months of December and July (p = 0.001). In
contrast, in Cajamarca, a marked peak of susceptible F. hepatica was observed between
the months of June to September (p < 0.001) while the proportion of resistant F. hepatica
fluctuated throughout the year without a discernible pattern (p < 0.001) (Figure 1).
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Table 2. Comparison of characteristics between F. hepatica specimens classified as susceptible or
resistant to TCBZ.SO and those classified as undetermined.
Variable

Category

Susceptible
N (%)

Undetermined
N (%)

Site

Cusco
Cajamarca
2020
2021
January
February
March
April
May
June
July
August
September
October
November
December
Kayra
Anta
San Jeronimo
Cajamarca
San Marcos
Bambamarca
Cajabamba

197 (20.4)
144 (24)
44 (21.6)
297 (21.8)
33 (34.4)
42 (25.1)
16 (23.5)
26 (17.6)
18 (18)
17 (18.5)
37 (25.9)
26 (27.4)
38 (19.8)
37 (23.7)
26 (15.9)
25 (17.4)
84 (18.5)
52 (20.6)
61 (23.6)
141 (25.8)
3 (37.5)
0 (0)
0 (0)

769 (79.6)
455 (76)
160 (78.4)
1064 (78.2)
63 (65.6)
125 (74.9)
52 (76.5)
122 (82.4)
82 (82)
75 (81.5)
106 (74.1)
69 (72.6)
154 (80.2)
119 (76.3)
138 (84.1)
119 (82.6)
371 (81.5)
200 (79.4)
198 (76.4)
406 (74.2)
5 (62.5)
36 (100)
8 (100)

Year
Month

Slaughterhouse

p
0.089
0.935
0.003

0.024

Resistant
N (%)

Undetermined
N (%)

375 (33.8)
87 (12.9)
149 (35.5)
313 (23)
42 (31.8)
79 (31.9)
30 (35.7)
29 (19.6)
34 (34)
28 (22.6)
39 (25.8)
18 (18.8)
50 (26)
34 (21.8)
42 (20.6)
37 (25)
183 (34.7)
98 (35.5)
94 (30.9)
82 (13.2)
3 (37.5)
0 (0)
2 (25)

733 (66.2)
588 (87.1)
271 (64.5)
1050 (77)
90 (68.2)
169 (68.1)
54 (64.3)
119 (80.4)
66 (66)
96 (77.4)
112 (74.2)
78 (81.3)
142 (74)
122 (78.2)
162 (79.4)
111 (75)
345 (65.3)
178 (64.5)
210 (69.1)
541 (86.8)
5 (62.5)
36 (100)
6 (75)

p
<0.001
<0.001
0.008

<0.001

3. Discussion
Resistance to TCBZ threatens F. hepatica control and treatment efforts in endemic areas
in developing and developed countries. The declining TCBZ effectiveness in fascioliasis can
impact the epidemiology of the disease in these regions. Characterizing fluke populations
by focusing on their TCBZ susceptibility profiles can provide insights into potential effects.
This is particularly important in the highlands of Peru where fascioliasis presents a large
burden to public health and livestock farming [6–9]. In the present study, we characterized
the susceptibility to TCBZ.SO of F. hepatica parasites collected from naturally infected
bovines brought for slaughter in representative abattoirs from the Cusco and Cajamarca
regions of Peru. TCBZ.SO is the most abundant and active metabolite of TCBZ. The
TCBZ metabolite’s activity depends on the tissue concentration of the drug, and this
is a function of the drug concentration in the medium and duration of exposure. The
experimental conditions in our study considered both variables to account for the slower
rates of tissue penetration of TCBZ.SO compared to the parent drug [33]. Thus, prior to our
main experiments, we adjusted the TCBZ.SO concentration and exposure time to establish
conditions that either inhibited 20% or 80% of the parasites. More than one in four parasites
exposed to TCBZ.SO for 24 h were classified as resistant. The distribution of the susceptible
and resistant parasites showed variations by location and time of collection. In addition,
morphometric differences were associated with susceptibility or resistance to TCBZ.SO.
A higher proportion of resistant F. hepatica was found in the Cusco region compared to
the Cajamarca region. Variation in TCBZ use and selective pressure among fluke populations may explain the differences between regions. The livestock industry in the Cajamarca
region is among the largest in Peru and ranks third in dairy production [34–36]. TCBZ was
the main medication used for control and was used 3–4 times a year with only transient
effects on infection incidence and intensity. High levels of TCBZ resistance have been
widely documented among cattle in Cajamarca [16,37]. However, TCBZ use has been
decreasing in the last 6–8 years and is no longer the preferred drug for livestock fascioliasis
control in the region, with drugs such as nitroxinil and clorsulon being used more often.
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Thus, TCBZ selective pressure on livestock fascioliasis has decreased in Cajamarca, possibly
in part contributing to identifying a lower proportion of resistant flukes. On the other hand,
municipal programs in Cusco’s study areas provide TCBZ to farmers, which is widely used
as the drug of choice. High TCBZ usage, deficiencies in dosing, and poor-quality control of
veterinary products are likely factors influencing the rapid emergence of resistance in the
Cusco area [38].
We observed monthly variations in the proportion of parasites classified as susceptible
or resistant, and the patterns were different in Cusco and Cajamarca. There are altitudinal
and climatic differences between these two regions that can, in part, explain these differences. Cajamarca in the north of Peru, near the border with Ecuador, is located at a lower
altitude and has higher maximal and minimal temperatures than Cusco, located in the
south at a higher altitude [39]. Although altitude is associated with a higher prevalence of
fascioliasis, temperature and solar radiation are associated with snail populations, infection
prevalence, incubation periods, and cercariae production [40–43]. Resistant and susceptible parasites have also been shown to have different pre-patent periods, production of
cercariae per snail, and infectivity capacity, which may give them a transmission advantage
depending on the region [23,44,45]. Importantly, patterns of TCBZ use in each region
could have also affected the proportions of susceptible and resistant parasites by selective
pressure [46,47]. Snail species and competence are other factors not well studied among
susceptible and resistant flukes. Further characterization of these field isolates in Cusco and
Cajamarca is underway to determine phenotypic and genotypic characteristics associated
with virulence.
The morphometric characteristics of F. hepatica have been shown to vary significantly
within and between parasite clones [45]. The geographic distribution of the parasites does
not seem to play a role in these differences [48]. We used adult F. hepatica body length as
a representative morphometric characteristic and determined that smaller parasites were
more likely to be susceptible to TCBZ.SO than larger parasites. The host species has been
associated with fluke size, but it is an unlikely explanation for our findings because 98% of
the parasites we tested were collected from cattle [49]. A crowding phenomenon has been
proposed in which F. hepatica parasites from livers with heavy infections have a smaller size
and produce fewer eggs than parasites collected from livers with light infections [50,51].
In our study, we did not perform systematic liver dissections and limited the number of
flukes collected to avoid sampling clones from each liver, which precluded the evaluation
of crowding as a potential cause of size differences. Other studies have detected size
differences between resistant and susceptible F. hepatica isolates. McConville et al. using
experimental infections in sheep reported that the Sligo TCBZ-resistant isolate was smaller
than the Cullompton TCBZ-susceptible isolate [23]. Although McConville et al.’s results
contrast with our findings, they may not be directly comparable as we characterized
parasites collected in the field, likely representing outcrossing populations. Lastly, the
smaller size of the susceptible parasites in our study might reflect the parasite’s age as
resistant parasites may live longer in cattle if they were treated with TCBZ at some point.
The scope of this study was limited to the collection of a selected group of parasites
obtained mostly from bovines after slaughter in formal abattoirs, which may not directly
reflect the spectrum of TCBZ susceptibility at the community level in livestock. However,
the proportions of susceptible and resistant parasites in our study provide information
about the patterns of TCBZ susceptibility in wildtype F. hepatica collected from different
endemic areas. The lack of specific cutoffs for TCBZ susceptibility in vitro among wildtype
F. hepatica forced us to establish definitions empirically. Thus, the reproducibility of our
results should be tested in other F. hepatica populations and at different time points. Abattoir
records contained scarce information about the animals taken for slaughter and farmers did
not keep detailed information about their animals. Thus, information about animals’ origin,
age, or prior treatment was often unavailable. We did not collect weather information,
which could have helped to evaluate the seasonal and yearly differences we found.
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In conclusion, the in vitro susceptibility to TCBZ in field populations of F. hepatica
parasites was associated with geographic, seasonal, and morphometric variations. Further
phenotypic and genotypic characterization of flukes at the extremes of the TCBZ susceptibility spectrum could aid in understanding the epidemiology and identifying markers
of resistance.
4. Materials and Methods
4.1. Parasite Procurement
We prospectively studied the in vitro TCBZ.SO susceptibility among adult F. hepatica
parasites collected from naturally infected bovids slaughtered in the Cusco (elevation
11152 ft) and Cajamarca (elevation 9022 ft) regions of the Peruvian highlands (Figure 2).
Trained field personnel retrieved condemned bovine livers in slaughterhouses and dissected
the intra- and extrahepatic biliary tree on the spot to collect adult parasites measuring
≥ 10 mm long. We collected up to 30–50 flukes per liver and batched them together
throughout the study. The parasites were placed in warm RPMI + Anti medium, prepared
with RPMI 1640 (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 100 units/mL
of penicillin, 100 µg/mL of streptomycin, and 0.25 µg/mL of amphotericin B (AntibioticAntimycotic, Gibco, Carlsbad, CA, USA), for transportation to our laboratories located
30 min to 3 h away. If it was known that an animal was treated for fascioliasis in the
last 6 months, the liver was not used for fluke collection. Upon arrival at the laboratory,
flukes were washed 5 times with normal saline solution at 37 ◦ C. Twenty-four fully motile
parasites (see below for motility scoring) were incubated at 37 ◦ C/5% CO2 . Parasites
were individually placed and incubated in 12-well plates containing 3 mL of RPMI + Anti
Pathogens 2022, 11, x FOR PEER REVIEWmedium supplemented with 5% fetal bovine serum (Biowest, Riverside, MO, USA), and
8 of 13
the medium was changed at 6 h and then every 12 h for 48 h. (Figure 3).
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Figure 2. Map of the Cusco and Cajamarca regions of Peru showing the location of the slaughter‐
houses (the size of the circles is proportional to the number of parasites collected at the site).

Figure 3. Flow diagram of the F. hepatica specimens collected and the selection procedures for test‐
Figure 3. Flow diagram of the F. hepatica specimens collected and the selection procedures for testing.
ing.

4.2. Definition of Parasite Viability and Experimental Conditions
We used a visual motility score to assess the viability of F. hepatica in vitro [25,52].
Parasites were assigned a score of 3+ if they exhibited active undulating movement, 2+
if the movement was slow or decreased but still easily perceptible by the naked eye, 1+
if the movement was only perceptible by observation under 20× magnification using
an inverted microscope, and 0+ if movement was not detected after observation under
20× magnification using an inverted microscope for two minutes [25,52].
The optimization of the experiments was performed in our Cusco site with flukes
collected from three selected local slaughterhouses. We used a stepwise approach to define
the TCBZ.SO exposure conditions that would identify the wildtype parasites with the
highest or lowest susceptibility to the drug. TCBZ.SO (Vetranal, Sigma-Aldrich, St. Louis,
MO, USA) was first dissolved in dimethyl-sulfoxide (DMSO) (Sigma-Aldrich, St. Louis,
MO, USA) and then diluted in RPMI + Anti medium at 37 ◦ C to prepare the exposure
medium. Only 12 fully motile flukes from each batch were selected randomly for exposure
experiments after the initial 48-h incubation period to decrease the chance of sampling
clone mates. Each selected fluke was incubated at 37 ◦ C/5% CO2 in individual wells of
12-well plates containing 3 mL of TCBZ.SO exposure medium. To optimize the conditions
to identify susceptible and resistant flukes, the starting TCBZ.SO concentrations were
7.5 µg/mL (16.6 µM) and 15 µg/mL (33.2 µM), respectively, and the exposure time was
set at 12 h [25,53–55]. Each plate included four control flukes incubated under the same
conditions but exposed to RPMI + Anti supplemented only with DMSO at the same
concentration used in the TCBZ.SO solutions. After exposure, the medium was replaced
with RPMI + Anti medium supplemented with 5% FBS and exchanged every 24 h thereafter
until the end of the observation period. The plate was considered invalid if >1 control fluke
had a motility score of 1+ or 0+ before the end of the observation period. We titrated the
drug concentrations and exposure times until we consistently identified 20% of the flukes
exposed to “susceptible” conditions with motility scores of 0+ or 1+ within the observation
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period and 80% of the flukes exposed to “resistant” conditions with motility scores of 0+ or
1+ within the observation period.
4.3. Susceptibility Testing of Wildtype F. hepatica
The final exposure conditions to identify susceptible flukes were TCBZ.SO at 15 µg/mL
(33.2 µM) for 12 h with 48 h of observation. The final exposure conditions to identify resistant flukes were TCBZ. SO at 15 µg/mL (33.2 µM), exchanged every 12 h for 24 h with
72 h of observation. Each fluke was incubated at 37 ◦ C/5% CO2 in a single well of 12-well
plates containing 3 mL of one of the TCBZ.SO exposure medium or control medium for the
specified time and then the solutions were exchanged for RPMI + Anti supplemented with
5% FBS every 24 h for the duration of the observation period. Flukes exposed to susceptible
conditions that developed motility scores of 0+ or 1+ within the time of exposure (12 h) or
the time of observation (48 h) were considered susceptible and those with motility scores 2+
or 3+ undetermined. Flukes exposed to resistant conditions with motility scores of 2+ and
3+ after 24 h of exposure and 72 h of observation were considered resistant and those with
motility scores of 0+ or 1+ were considered undetermined. We collected flukes during
the years 2020 and 2021 from slaughterhouses in Cusco and Cajamarca. The three largest
and most accessible slaughterhouses in each region were selected for weekly F. hepatica
collections. Information on the batch, collection location, month, year, parasite length, and
previous TCBZ treatment was collected when available. Fluke numbers varied per month
and per site due to COVID-19 disruptions.
4.4. Statistical Analysis
Data were analyzed using the Statistical Package for the Social Sciences software
version 25.0 (SPSS, Inc., Chicago, IL, USA). Proportions and means ± standard deviations
were calculated to describe the distribution of categorical and continuous variables as
appropriate. Chi-square and Student T-tests were used to compare the distribution of the
categorical and continuous variables, respectively. A p-value < 0.05 was used to define
statistical significance.
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